Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6092355 | Gastroenterology | 2015 | 26 Pages |
Abstract
In an uncontrolled, open-label trial, high rates of SVR12 were achieved by patients with HCV genotype 3 infection who received 12 weeks of ledipasvir and sofosbuvir plus ribavirin, and by patients with HCV genotype 6 infection who received 12 weeks of sofosbuvir and ledipasvir without ribavirin. Current guidelines do not recommend the use of ledipasvir and sofosbuvir, with or without ribavirin, in patients with HCV genotype 3 infection. ClinicalTrials.gov Number: NCT01826981.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Edward J. Gane, Robert H. Hyland, Di An, Evguenia Svarovskaia, Phillip S. Pang, Diana Brainard, Catherine A. Stedman,